HR positive/HER-2 negative breast cancer
Clinical trials for HR positive/HER-2 negative breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR positive/HER-2 negative breast cancer trials appear
Sign up with your email to follow new studies for HR positive/HER-2 negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can adding capivasertib slow metastatic breast cancer?
Disease control Not yet recruitingThis trial tests whether adding the investigational drug capivasertib to standard hormone-blocking therapy and a CDK4/6 inhibitor can improve treatment response in people with HR-positive, HER2-negative metastatic breast cancer. Participants receive either the standard treatment …
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests whether adding an immune-boosting drug called eftilagimod alpha to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage hormone receptor-positive, HER2-negative breast cancer. About 50 participants will receive the drug …
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase 2 • Sponsor: George Washington University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC